Status:
RECRUITING
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Lead Sponsor:
Northwestern University
Conditions:
Ovary Cancer
Endometrial Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care c...
Detailed Description
Uterine cancer is the most common gynecologic cancer diagnosed in women and the fourth most common cancer to be diagnosed in females with an estimated 65,950 cases that will be diagnosed this year in ...
Eligibility Criteria
Inclusion
- Female; ≥ 18 years of age
- Confirmed or high suspicion for endometrial, ovarian, fallopian tube or primary peritoneal cancer, and are able and expecting to undergo adjuvant chemotherapy following hysterectomy for treatment of disease, as determined by their treating physician
- Fluent in spoken and written English
- Own a smart phone
- Have access to the internet to complete surveys
- ECOG status of 0 or 1
- Willingness to sign informed consent form
Exclusion
- Patients who are not planning to undergo chemotherapy at Northwestern Medicine
- Patients engaged in shift work (i.e., those who work nights, 3rd shift)
- BMI of 50+ or those with a diagnosed eating disorder. Patients who take medications for blood glucose regulation (e.g. insulin), and/or require treatment with therapeutic doses of anticoagulants will be excluded.
- Patients who have been diagnosed with medication-dependent diabetes, recent myocardial infarction, stroke, pulmonary embolus, renal failure, or any condition that may preclude ability to tolerate a short-term fast will be excluded.
- Patients who take medications where conditions may be influenced in the presence of fasting (e.g. hypertension, electrolyte abnormalities, migraines) will be monitored by their treating physician for any necessary adjustments in these medications.
- Patients whose oncologist has not provided clearance for their participation
- Unable or unwilling to follow a diet regimen or participate in ketone measurements
- ECOG status greater than 1
- Patients who have undergone prior systemic therapy to treat a malignancy in the last 2 years.
Key Trial Info
Start Date :
October 16 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05990426
Start Date
October 16 2023
End Date
August 1 2026
Last Update
December 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611